Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.94)
# 1,667
Out of 5,105 analysts
137
Total ratings
54.46%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $21.53 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $70.09 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $741.29 | +14.66% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.47 | +1,124.49% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.16 | +5,072.41% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.64 | +448.78% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $9.61 | +253.80% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $174.10 | +87.82% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $36.80 | +1,443.48% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $452.04 | -37.84% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.66 | +381.93% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.15 | +8,421.74% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $317.74 | -7.16% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $120.40 | -28.57% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $31.35 | +53.11% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.45 | +302.68% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.27 | +164.03% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $2.12 | +135.85% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $95.41 | +4.81% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $220.42 | -8.81% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $75.64 | +12.37% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.85 | +101.89% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $21.53 | +907.90% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $44.94 | +6.81% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $18.07 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $397.55 | -61.26% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $53.31 | +117.60% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $5.86 | +1,708.87% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $9.02 | +210.42% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $182.28 | -55.01% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $493.99 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.15 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.53
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.09
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $741.29
Upside: +14.66%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.47
Upside: +1,124.49%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.16
Upside: +5,072.41%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.64
Upside: +448.78%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $9.61
Upside: +253.80%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $174.10
Upside: +87.82%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $36.80
Upside: +1,443.48%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $452.04
Upside: -37.84%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.66
Upside: +381.93%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.15
Upside: +8,421.74%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $317.74
Upside: -7.16%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $120.40
Upside: -28.57%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $31.35
Upside: +53.11%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.45
Upside: +302.68%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.27
Upside: +164.03%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $2.12
Upside: +135.85%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $95.41
Upside: +4.81%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $220.42
Upside: -8.81%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $75.64
Upside: +12.37%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.85
Upside: +101.89%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $21.53
Upside: +907.90%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $44.94
Upside: +6.81%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $18.07
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $397.55
Upside: -61.26%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $53.31
Upside: +117.60%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $5.86
Upside: +1,708.87%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $9.02
Upside: +210.42%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $182.28
Upside: -55.01%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $493.99
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.15
Upside: -